Israeli pharmaceutical giant Teva gets FDA approval for leukemia drug
Synribo treats a type of chronic myelogenous leukemia in patients whose cancer has progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors.
The U.S. Food and Drug Administration on Friday said it has approved a new leukemia treatment from Teva Pharmaceutical Industries Ltd to be sold under the brand name Synribo.
register with haaretz
Like us on Facebook and get articles directly in your news feed